ACSChemNeurosci

This account will no longer be active or monitored. We welcome our community to follow @ACSPublications or sign up for e-Alerts for future updates from ACS Chemical Neuroscience: go.acs.org/cbL

Don't miss out on this exciting discussion! This collection from #ACSChemNeuro dives into the research around #MDMA as a potential breakthrough therapy Read the latest research ➡ go.acs.org/bMR

Next week is World #AntimicrobialResistance Awareness Week! Join us for a webinar discussing the cutting edge work being done to fight multi-drug resistant bacteria. 🦠 📅 Wed Nov 20, 11am EST. Register here ➡️ go.acs.org/bF7

Check out our recent works on Chronic pain published @ACSChemNeurosci A great collaboration between @DarrenDerksen lab and @zymedyne Many thanks to @MitacsCanada for the funding!

Don't miss out on this exciting discussion! This collection from #ACSChemNeuro dives into the research around #MDMA as a potential breakthrough therapy Read the latest research ➡ go.acs.org/auk

Curious about the latest research on MDMA treatments? Check out our recent collection of articles on the subject ➡ go.acs.org/arI

❗ LAST CALL! Call for Papers: ACS Pharmacology and Translational Science invites submissions for a Virtual Special Issue on new perspectives and advances in translational #pain research to treat pain. Submit papers by August 1, 2024 ➡ go.acs.org/ajc

I am proud to have collaborated with @cahhcardi et al in this amazing paper now published in @ACSChemNeurosci. Link: pubs.acs.org/doi/10.1021/ac… @Ariel_Lab

📢Stay up to date with the latest📢 This new collection of #ACSChemNeuro research joins the discussion around #MDMA as a potential breakthrough therapy Read the latest research ➡ go.acs.org/a9I

📢Stay up to date with the latest📢 This new collection of #ACSChemNeuro research joins the discussion around #MDMA as a potential breakthrough therapy Read the latest research ➡ go.acs.org/9Ze

Read our latest review on the gut-microbiome brain axis in Parkinson’s disease and role of “biotics” approach #neuroscience #gutmicrobiota @ACSChemNeurosci pubs.acs.org/doi/10.1021/ac…

📢Stay up to date with the latest📢 This new collection of #ACSChemNeuro research joins the discussion around #MDMA as a potential breakthrough therapy Read the latest research ➡ go.acs.org/9Mn

#research Parallel Metabolomics and Lipidomics of a PSMA/GCPII Deficient Mouse Model Reveal Alteration of NAAG Levels and Brain Lipid Composition (Friedecký, @konvalinka_jan) - @ACSChemNeurosci: doi.org/10.1021/acsche… @FriedeckyGroup @IOCBPrague @CzechAcademy @UPOlomouc

To sum up today's adcomm: While the experts saw potential in the use of MDMA-assisted therapy in the treatment of PTSD, there were too many confounding variables and possible safety concerns to push for approval #Lykos

FDA Advisory Committee votes against recommending Lykos' #MDMA treatment for PTSD Read our latest MDMA research here ➡ go.acs.org/9Er

@jmhooker @zenbrainest want to kick off the discussion?

Fascinating discussions online today surrounding the FDA's consideration of a new #MDMA treatment for PTSD 🤔 When is a double-blinded study not enough? How can you blind for a treatment that includes such pronounced and well-known effects? Let us know what you think! ⬇

📢New collection of #ACSChemNeuro research as the FDA is expected to announce a decision on a new treatment involving #MDMA today ⏰ Read the latest research ➡ go.acs.org/9Er

It's all things adamantane in our (@Lambert_Usyd) latest synthetic cannabinoid work, out now in @ACSChemNeurosci! We synthesised and evaluated a library of adamantane-derived SCRAs, including fluorinated and deuterated analogues 🧪 🧵 pubs.acs.org/doi/10.1021/ac…

This study builds on our @ACSChemNeurosci paper last year, where @PashaDavoudian mapped c-Fos response in the brain after psilocybin or ketamine, identifying the list of shared and distinct brain regions impacted by the drugs pubs.acs.org/doi/10.1021/ac…